Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;95(52):e5705.
doi: 10.1097/MD.0000000000005705.

Application of dual-energy spectral CT imaging in differential diagnosis of bladder cancer and benign prostate hyperplasia

Affiliations

Application of dual-energy spectral CT imaging in differential diagnosis of bladder cancer and benign prostate hyperplasia

Anliang Chen et al. Medicine (Baltimore). 2016 Dec.

Abstract

The aim of this study was to explore the clinical value of dual-energy spectral CT imaging in the differential diagnosis between bladder cancer and benign prostate hyperplasia (BPH).We retrospectively analyzed images of 118 patients who received pelvic dual-energy spectral CT imaging. These patients were later confirmed to have bladder cancer in 61 patients and BPH in 57 patients. CT values of the 2 lesion types from 40 to 140 keV were measured from the monochromatic spectral CT image to generate spectral HU curves. The slope of the spectral curve and the lesion effective atomic number were calculated. The measured parameters were analyzed with independent-sample Mann-Whitney U test.There was a statistically significant difference in CT value between the 2 groups from 40 to 90 keV, with the biggest difference at 40 keV (median and interquartile range: 83.3 HU and 22.9 HU vs 60.6 HU and 16.7 HU, Z = 5.932, P < 0.001). The slope of the spectral HU curve for bladder cancer was markedly higher than that of BPH (median and interquartile range: 0.48 and 0.23 vs 0.26 and 0.22, Z = 5.162, P < 0.001); the difference in effective atomic number (median and interquartile range: 7.99 and 0.21 vs 7.80 and 0.20, Z = 5.233, P < 0.001) was also statistically significant.Dual-energy spectral CT imaging provides high sensitivity and specificity for differentiating bladder cancer from benign prostate hyperplasia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1
Monochromatic 70 keV axial image of a 72-year-old patient with bladder cancer on the posterior wall (A) and the next neighbouring layers (C, D). It did not distinguish between the bladder cancer and prostate. Curve on the right (B) shows the CT number as function of photon energy for the bladder cancer.
Figure 2
Figure 2
Monochromatic 70 keV axial image of a 83-year-old patient with benign prostate hyperplasia (A) and the next neighbouring layers (C, D). Curve on the right (B) shows the CT number as function of photon energy.
Figure 3
Figure 3
Direct comparison of the mean CT number as function of photon energy for bladder cancer (n = 61) and benign prostate hyperplasia (BPH) (n = 57). The slope of the curve for bladder cancer was significantly greater than that of BPH.
Figure 4
Figure 4
Receiver-operating characteristics (ROC) curves with CT number at 40 keV, Eff-Z number, and slope of spectral HU curve (k) for the diagnosis of bladder cancer: the AUC were 0.817, 0.779, 0.776, respectively.

References

    1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. Cancer J Clin 2014;64:9–29. - PubMed
    1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Cancer J Clin 2016;66:115–32. - PubMed
    1. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009;36:403–15. - PubMed
    1. Gosling JA, Kung LS, Dixon JS, et al. Correlation between the structure and function of the rabbit urinary bladder following partial outlet obstruction. J Urol 2000;163:1349–56. - PubMed
    1. Li S, Zeng XT, Ruan XL, et al. Simultaneous transurethral resection of bladder cancer and prostate may reduce recurrence rates: A systematic review and meta-analysis. Experiment Ther Med 2012;4:685–92. - PMC - PubMed